Reference number : 172-2021-2022-Q2-976618, amendment number : , agreement type : C, recipient legal name : Providence Therapeutics Holdings Inc., recipient country : CA, recipient province : AB, recipient city : Calgary|Calgary, recipient postal code : T2Z 3P4, program name english : Industrial Research Assistance Program – Contributions to Firms, program name french : Programme d’aide à la recherche industrielle – Contributions aux entreprises, program purpose english : The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization, program purpose french : Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation, agreement title english : Providence COVID-19 Vaccine Development - Stage 2, agreement title french : Développement du vaccin Providence COVID-19 - Phase 2, agreement number : 976618, agreement value : 8600000.0, agreement start date : 2021-07-23, agreement end date : 2022-11-30, description english : The Firm is Canada's leader in mRNA therapeutics and this project's main goal is to continue the development of PTX-COVID19-B by conducting a Phase II clinical trial with the goal of commercializing a made-in-Canada COVID-19 mRNA vaccine and the development and validation of mRNA vaccines targeting COVID-19 Variants of Concern., description french : L'entreprise est le chef de file canadien dans le domaine des ARNm thérapeutiques et le principal objectif de ce projet est de poursuivre le développement du PTX-COVID19-B en menant un essai clinique de phase II. Le but est de commercialiser un vaccin à ARNm COVID-19 fabriqué au Canada et de développer et valider des vaccins à ARNm ciblant les variants préoccupants de la COVID-19., expected results english : The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization, expected results french : Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation, additional information english : nan, additional information french : nan, owner organization : nrc-cnrc, owner organization title : National Research Council Canada | Conseil national de recherches Canada